Emergent BioSolutions Inc NYSE: EBS
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Name | Emergent BioSolutions Inc |
Ticker | EBS |
Exchange | NYSE |
Sector | Health Care |
Industry | Drug Manufacturers - Diversified |
Price | 106.29 |
52W Low/High | 49.34 / 134.94 |
Market cap | 5.6 B |
1Y Total Return |
91.31%
Strong |
1Y Volatility |
70.04%
More Risk |
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Details
Ticker | EBS |
Name | Emergent BioSolutions Inc |
ISIN | US29089Q1058 |
CUSIP | 29089Q105 |
Exchange | NYSE |
Sector | Health Care |
Industry | Drug Manufacturers - Diversified |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) | US S&P Small Cap 600 |
Share as of 1/15/21
Close Price | 106.29 |
52W Low/High | 49.34 / 134.94 |
Market cap | 5.6 B |
1Y Total Return |
91.31%
Strong |
1Y Volatility |
70.04%
More Risk |
Beta | 1.51 |
PE (trailing) |
34.18
Above Average |
12M Dividends | - |
Last Dividend Date | 8/1/16 |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | 12.5% |
Cash from Op. / Cur. Liabilities | 1.38 |
Diluted Earnings / Share | 3.11 |
ROE | 14.6% |
ROIC | -70.7% |
Price / Revenue | 4.3 |
Price / Book | 4.6 |
Price / CF | 14.0 |
Current Ratio | 3.2 |
Cur.Liabilities / Tot.Liabilities | 0.2 |
Financial Leverage | 0.70 |
in Mils USD |
rolling-year up to September
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
1,333
|
1,016
|
705
|
519
|
497
|
450
|
|
Gross Profit |
844
|
602
|
434
|
360
|
369
|
353
|
|
R&D |
238
|
215
|
119
|
95
|
107
|
107
|
|
EBITDA |
371
|
155
|
182
|
169
|
133
|
145
|
|
Operating Income |
253
|
48
|
132
|
122
|
120
|
132
|
|
Net Income exc. Extra |
167
|
4
|
100
|
86
|
48
|
60
|
|
per Share | |||||||
Diluted avg Shares |
54
|
52
|
52
|
50
|
49
|
48
|
|
EPS exc. Extra |
3.11
|
0.07
|
1.97
|
1.79
|
1.00
|
1.25
|
|
Dividend |
-
|
-
|
-
|
-
|
2.00
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
6.34%
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
2,616
|
2,334
|
1,174
|
1,024
|
932
|
977
|
|
Cash, Eq & Invt ShortTerm |
415
|
139
|
340
|
342
|
299
|
309
|
|
Total Current Assets |
959
|
700
|
563
|
556
|
480
|
473
|
|
Total Non-Current Assets |
1,658
|
1,634
|
610
|
468
|
452
|
503
|
|
Intangibles |
945
|
996
|
157
|
70
|
76
|
112
|
|
Total Liabilities |
1,365
|
1,299
|
207
|
360
|
384
|
371
|
|
Total Current Liabilities |
299
|
275
|
102
|
75
|
110
|
89
|
|
Long Term Debt |
1,066
|
1,024
|
105
|
285
|
274
|
283
|
|
Shareholder equity |
1,252
|
1,035
|
967
|
664
|
548
|
605
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
413
|
-100
|
285
|
118
|
68
|
93
|
|
Depreciation |
114
|
108
|
50
|
40
|
38
|
34
|
|
Cash from Investing |
-151
|
-909
|
-256
|
-62
|
-68
|
-51
|
|
Capex |
141
|
72
|
64
|
62
|
67
|
50
|
|
Cash from Financing |
14
|
808
|
-30
|
-13
|
-10
|
24
|
|
Stock Issued |
29
|
10
|
-13
|
13
|
25
|
19
|
|
Debt (LT) Issued |
47
|
808
|
0
|
-21
|
0
|
2
|
|
Free Cash Flow |
-1,436
|
-52
|
71
|
-31
|
27
|
-92
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
12.5%
|
0.4%
|
14.2%
|
16.6%
|
9.6%
|
13.2%
|
|
NCFO / Op.Income |
163.0%
|
-209.4%
|
216.5%
|
96.6%
|
57.1%
|
70.6%
|
|
Current Ratio |
3.2
|
2.5
|
5.5
|
7.4
|
4.4
|
5.3
|
|
Financial Leverage D/E |
0.70
|
0.80
|
0.01
|
0.38
|
0.49
|
0.42
|
|
Return on Capital Avg |
-70.7%
|
3.4%
|
14.9%
|
13.8%
|
10.6%
|
-7.7%
|
|
Return on Shareholder Equity |
14.6%
|
0.4%
|
12.3%
|
14.2%
|
8.3%
|
10.7%
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available